DeepMed Research

DermBiont, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Holding

Established: 2017-01-01

Employees: 51

Market Cap: -

Website: http://www.dermbiont.com

Clinical Trials

Randomized Study Using SM-030 Gel for Adults With Melasma

Phase 2

Recruiting

Conditions: Melasma

Interventions: Drug: SM-030 gel 0.64%
Drug: Placebo gel
Drug: SM-030 gel 0.08%

First Posted Date: 2024-06-12

Last Posted Date: 2024-12-13

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 138

Registration Number: NCT06454747

Locations: 🇸🇻
Centro de Investigación y Desarrollo Brioso Ramirez, Santa Tecla, La Libertad, El Salvador, El Salvador
🇸🇻
Zepeda Dermatologia, Santa Tecla, La Libertad, El Salvador

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers

Phase 2

Recruiting

Conditions: Non-Melanoma Skin Cancers

Interventions: Drug: SM-020 1% Gel

First Posted Date: 2024-05-10

Last Posted Date: 2024-05-10

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 50

Registration Number: NCT06409195

Locations: 🇺🇸
Dermatology, Laser and Vein Specialist, Charlotte, North Carolina, United States

A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

Phase 2

Recruiting

Conditions: Seborrheic Keratosis

Interventions: Drug: SM-020 gel 1.0%
Drug: Vehicle gel

First Posted Date: 2023-10-30

Last Posted Date: 2024-05-10

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 60

Registration Number: NCT06108024

Locations: 🇺🇸
Driven Research LLC, Coral Gables, Florida, United States
🇺🇸
Minnesota Clinical Study Center, New Brighton, Minnesota, United States
🇺🇸
Oregon Dermatology and Research Center, Portland, Oregon, United States

and more 1 locations

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)

Phase 2

Active, not recruiting

Conditions: Dermatosis Papulosa Nigra

Interventions: Drug: SM-020 gel 1.0%

First Posted Date: 2023-10-25

Last Posted Date: 2024-05-01

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 10

Registration Number: NCT06099080

Locations: 🇺🇸
Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California, United States

Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos

Phase 2

Completed

Conditions: Hyperpigmentation

Interventions: Drug: Vehicle gel
Drug: DBI-102
Drug: Hydroquinone Cream

First Posted Date: 2022-08-23

Last Posted Date: 2023-10-25

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 75

Registration Number: NCT05511948

Locations: 🇸🇻
Zepeda Dermatologia, Santa Tecla, La Libertad, El Salvador

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Phase 2

Active, not recruiting

Conditions: Tinea Pedis

Interventions: Biological: DBI-002 Gel
Biological: DBI-001 Gel
Biological: Aqueous Gel

First Posted Date: 2022-08-09

Last Posted Date: 2023-02-14

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 24

Registration Number: NCT05493488

Locations: 🇺🇸
Oregon Dermatology and Research, Portland, Oregon, United States
🇺🇸
Premier Clinical Research, Spokane, Washington, United States

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Phase 2

Suspended

Conditions: Onychomycosis

Interventions: Biological: Aqueous Gel
Biological: DBI-002
Biological: DBI-001

First Posted Date: 2022-08-08

Last Posted Date: 2023-09-07

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 60

Registration Number: NCT05491603

Locations: 🇺🇸
DermResearch, Austin, Texas, United States
🇺🇸
North Sound Dermatology, Mill Creek, Washington, United States
🇺🇸
Minnesota Clinical Study Center, New Brighton, Minnesota, United States

and more 2 locations

Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Biological: Aqueous gel
Biological: DBI-001

First Posted Date: 2022-02-24

Last Posted Date: 2023-11-08

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 10

Registration Number: NCT05253755

Locations: 🇺🇸
Investigate MD, LLC, Scottsdale, Arizona, United States
🇺🇸
North Sound Dermatology, Mill Creek, Washington, United States
🇺🇸
DermResearch, Inc., Austin, Texas, United States

Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis

Phase 2

Active, not recruiting

Conditions: Seborrheic Keratosis

Interventions: Drug: SM-020

First Posted Date: 2021-11-29

Last Posted Date: 2023-10-03

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 70

Registration Number: NCT05136144

Locations: 🇸🇻
Zepeda Dermatologia, Santa Tecla, La Libertad, El Salvador

A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor

Phase 2

Completed

Conditions: Tinea Versicolor

Interventions: Biological: DBI-002 probiotic gel
Biological: Aqueous gel

First Posted Date: 2021-06-24

Last Posted Date: 2021-11-29

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 34

Registration Number: NCT04937920

Locations: 🇸🇻
Zepeda Dermatologia, Santa Tecla, La Libertad, El Salvador

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy